Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs MP Materials (MP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs MP Materials — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while MP Materials trades at $39.86 (market cap $7.56B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and MP Materials for 14 Days on average.
| KYMR | MP | |
|---|---|---|
Market Cap | $8.87B | $7.56B |
Volume | 779,107 | 5,062,845 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $89.85 |
52-Week Low | $55.80 | $38.10 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $8.26B | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MP Materials (MP) trades at $42.43, down 2.14% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability metrics with a -19.85% net income margin and -4.08% ROE, though revenue growth is projected from $224M in 2025 to $305M in 2026. Analyst sentiment remains strongly bullish with 13 buy ratings and a $80.70 consensus price target, representing significant upside potential from current levels despite recent price weakness.
The investment case hinges on MP's strategic position in rare earths production and U.S. government support for domestic supply chains. Key risks include persistent negative cash flow from operations, high valuation multiples (P/S 24.64), and sector volatility. The upcoming Q3 2026 earnings report on November 5 will be critical for validating the company's growth trajectory and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About MP Materials
MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →
